At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
SB-525 (PF-07055480)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1/2, OPEN-LABEL, ADAPTIVE, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF SB-525 (PF-07055480) (RECOMBINANT AAV2/6 HUMAN FACTOR 8 GENE THERAPY) IN ADULT SUBJECTS WITH SEVERE HEMOPHILIA A
In Brief
A Phase 2 clinical trial evaluating SB-525 (PF-07055480) for Hemophilia A. Completed, enrolled 13 participants across 22 sites.
Detailed Summary
The purpose of the study is to evaluate the safety, tolerability and time-course profile of FVIII activity after dosing with SB-525 (PF-07055480)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemophilia A
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartJun 2017
Primary CompletionJul 2024
TodayJul 2026
First PostedFeb 23, 2017
Enrollment StartJun 21, 2017
Primary CompletionJul 16, 2024
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 9.4 years ago
Interventions
SB-525 (PF-07055480)biological
Single dose of investigational product SB-525 (PF-07055480)